Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zelenectide Pevedotin in NECTIN4 Amplified Advanced Breast Cancer
NCT06840483Phase 2Active, not recruiting
- Sponsor
- Bicycle Therapeutics
- Start
- Mar 2025
- Primary completion
- Jun 2028
- Modality
- Cyclic Peptides, Antibody-Drug Conjugates (ADCs), Peptide-Drug Conjugates
- Countries
- 7
01
Overview
Phase 2, open-label trial of zelenectide pevedotin in breast cancer (2 cohorts), sponsored by Bicycle Therapeutics. Primary endpoint: Objective Response Rate at 3 years. Started Mar 2025; status: active, not recruiting.
02
Drugs
zelenectide pevedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06840483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06840483.